Furaprevir clinical trials
Also written TG-2349.
How each study uses furaprevir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TG-2349
- 3
Studies by the year they started
6 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
TaiGen Biotechnology Co., Ltd. (3) · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. (3)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses furaprevir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedPhase 2TaiGen Biotechnology Co., Ltd.NCT02340962Written as TG-2349
- A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I PatientsCompletedPhase 3Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.NCT04155515Written as TG-2349
- To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349CompletedPhase 1Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.NCT03610867Written as Furaprevir capsule (SAD)
- To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese VolunteersCompletedPhase 1Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.NCT03610880Written as TG-2349 (400 mg) plus DAG181 (200 mg)
- Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy VolunteersCompletedPhase 1TaiGen Biotechnology Co., Ltd.NCT02108418Written as TG-2349 as the original formulation
- A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected PatientsCompletedPhase 1TaiGen Biotechnology Co., Ltd.NCT01523990Written as TG-2349
Codes
What other systems call furaprevir · ClinicalTrials.gg INT014235
- UNII (FDA) 0UMM44REU9FURAPREVIRConfirmed FDA, Wikidata
- Wikidata Q27237271furaprevirConfirmed FDA, Wikidata
- NCI Thesaurus C166437FuraprevirOne source FDA
- DrugBank DB12785One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0UMM44REU9 | FURAPREVIR | Confirmed FDA, Wikidata |
| Wikidata | Q27237271 | furaprevir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166437 | Furaprevir | One source FDA |
| DrugBank | DB12785 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.